转移抑制基因KAI1在非小细胞肺癌中的表达及意义

Significance of Metastasis Suppressor Gene KAI1 Expression with Non-Small Cell Lung Cancer

目的研究非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)肿瘤转移抑制基因(Metastasis Suppressor Gene,MSG)KAI1的表达特点,探讨肿瘤转移抑制基因KAI1在非小细胞肺癌中表达下调或缺失与肿瘤临床病理因素之间的关系。方法应用免疫组化Elivision二步法检测KAI1在68例NSCLC组织和对照组癌旁组织中的表达,对检测结果与非小细胞肺癌的临床病理参数作统计学分析。结果①癌旁组织内KAI1的表达阳性率为77.9%,NSCLC组织内KAI1的表达阳性率为60.3%,二者相比差异有统计学意义(P<0.05)。②以有无淋巴结转移进行分组,KAI1的表达阳性率分别为30.3%、88.6%,两组相比有统计学意义(P<0.05);以(高分化+中分化)和(低分化+未分化)进行分组,NSCLC肿瘤组织内KAI1的表达阳性率分别为82.5%、28.6%,二者相比差异有统计学意义(P<0.05);以(Ⅰ+Ⅱ)期和Ⅲa期进行分组,其KAI1的表达阳性率分别为81.8%、20.8%,两组相比有统计学意义(P<0.05)。结论通过对NSCLC组织内肿瘤转移抑制基因KAI1表达的检测,发现其在有淋巴结转移、低分化及分期较晚患者中呈低表达,从而为NSCLC基因治疗提供理论依据。

Objective To investigate the expression of the KAI1, one of metastasis suppressor genes, in Non-Small Cell Lung Cancer（ NSCLC ） and the relationship between down-regulation or lack of the KAI1 and their clinicopathological parameters. Methods The expression of KAI1 was detected in the tumor and at the edge of it in 68 paraffin sections of NSCLC by immunohistochemistry（ Elivision Methods）, and the results were analyzed with clinicopathological parameters. Results （1）The positive rate of KAI1 at the edge of tumor（77.9% ） was significantly higher than that in it（60.3% ） ,P 〈0.05 ;（2）The difference of positive rate of KAI1 was significant between group 1 （with metastasis of lymph node） and group 2 （without metastasis of lymph node ）, P 〈 0.05, there was significant difference between the well differentiated group （82.5 % ） and the poor differentiated group （28.6%） ,P〈0.05,KAI1 in the（ Ⅰ ＋ Ⅱ ） stage（81.8% ） was distinctly higher than that in the Ⅲa stage（20.8% ）,P 〈 0.05. Conclusion In the patients of NSCLC, the expression of KAI1 was lower in the group with metastasis of lymph node, poor differentiation and advanced stage, which may provide a theoretical basis of gene therapy for NSCLC.